| |
|
|
Literaturstellen
|
Zugang
zum anklicken
|
| Artikel zum Thema aus unserem Institut |
|
| U. Sancken, I. Bartels (1999) Der sogenannte Triple-Test - Ergebnisse und Erfahrungen aus einer 10 jährigen Laborroutine. Reproduktionsmedizin 15, 276-284 |
|
| Sancken U, Bartels I, Louwen F, Eiben B (1999) A retrospective evaluation of second-trimester serum screening for fetal trisomy 18: experience of two laboratories. Prenat Diagn 19, 947-54 |
|
| Sancken, U., Rempen, A. (1998) Die Bedeutung des Schwangerschaftsalters bei der individuellen Risikoberechnung für ein fetales Down-Syndrom in der sogenannten Triple-Diagnostik. Geburtshilfe und Frauenheilkunde 58, 219-224 |
|
| Moghadam, S., Engel, W., Bougoussa, M., Hennen, G., Igout, A., Sancken, U. (1998) Maternal serum placental growth hormone and insulin like growth factor binding proteins 1 and 3 in pregnancies affected by fetal aneuploidy and other abnormalities: implications for prenatal diagnosis of trisomy 21. Fetal Diagnosis and Therapy 13, 291-297 |
|
| Bartels, I. (1997) Serummarker zur Erkennung von fetalen Chromosomenstörungen. Archives of Gynecology and Obstetrics 260, 95-98 |
|
| Zimmermann, R., Reynolds, T. M., John, R., Spencer, K., Bartels, I., Coombes, E., Trevor, S. (1996) Age-Independent indices in second-trimester serum screening for Down's Syndrome are useless. Prenatal Diagnosis, 16, 79-82 |
|
| Eiben, B., Sancken, U. (1996) Computer software programs and Down's syndrome risk calculations. The Lancet 347, 1553-1554 |
|
| Sancken, U., Bahner, D. (1995) The effect of thermal instability of intact human chorionic gonadotropin (ihCG) on the application of its free ß-subunit (free ßhCG) as a serum marker in Down Syndrome screening. Prenatal Diagnosis 15, 731-738 |
|
| Bartels, I., Sancken, U. (1994) Pränataler Risikoindex für fetales Down Syndrom mit Serummarkern. Zeitschrift für Geburtshilfe und Perinatologie 198, 153-154 |
|
| Bartels, I., Sancken, U. (1994) [Prenatal risk index for fetal Down's syndrome with serum markers. Comment on the contribution by R. Benz, U. Muller, M. Krahner-Pilat, S. Wagner-Geuder, R. Terinde: Serum screening for Down's syndrome in women less than 35 years of age with an age-independent index]. Z Geburtshilfe Perinatol. 198, Diskussion 155-6. |
|
| Bartels, I., Bockel, B., Caesar, J., Krawczak, M., Thiele, M., Rauskolb, R. (1994) Risk of fetal Down's syndrome based on maternal age and varying combinations ofmaternal serum markers. Archives of Gynecology and Obstetrics 255, 57-64 |
|
| Bartels, I., Caesar, J., Sancken, U. (1994) Prenatal detection of X-linked ichthyosis by maternal serum screening for Down syndrome. Prenatal Diagnosis 14, 227-229 |
|
| Bartels, I., Hoppe-Sievert, B., Bockel, B., Herold, S., Caesar, J. (1993) Adjustment formulare for maternal serum Alpha-Fetoprotein, human chorionic gonadotropin and unconjugated oestriol to maternal weight and smoking. Prenatal Diagnosis 13, 123-130 |
|
| Bartels I, Thiele M, Bogart MH (1990) Maternal serum hCG and SP1 in pregnancies with fetal aneuploidy. Am J Med Genet, 37, 261-4 |
|
| Bartels I, Lindemann A (1988) Maternal levels of pregnancy-specific beta 1-glycoprotein (SP-1) are elevated in pregnancies affected by Down's syndrome. Hum Genet 80, 46-8 |
|
|
|
| Schwerpunktthema Methoden |
|
| Cole LA, Shahabi S, Oz UA, Bahado-Singh RO, Mahoney MJ (1999) Hyperglycosylated human chorionic gonadotropin (invasive trophoblastantigen) immunoassay: A new basis for gestational Down syndrome screening. Clin Chem, 45, 2109-19 |
|
| Wald NJ, Watt HC, Hackshaw AK (1999) Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 341, 461-7 |
|
| Bahado-Singh R, Oz U, Rinne K, Hunter D, Cole L, Mahoney MJ, Baumgarten A (1999) Elevated maternal urine level of beta-core fragment of human chorionic gonadotropin versus serum triple test in the second-trimester detection of down syndrome. Am J Obstet Gynecol, 181, 929-33 |
|
| Cole LA, Rinne KM, Mahajan SM, Oz UA, Shahabi S, Mahoney MJ, Bahado-Singh RO (1999) Urinary screening tests for fetal Down syndrome: I. Fresh beta-core fragment. Prenat Diagn 19, 340-50 (Kommentar: Grundsatzartikel) |
|
Cole LA, Rinne KM, Mahajan SM, Oz UA, Shahabi S, Mahoney MJ, Bahado-Singh RO (1999) Urinary screening tests for fetal Down syndrome: II. Hyperglycosylated
hCG. Prenat Diagn 19, 351-9 (Kommentar: Grundsatzartikel) |
|
| E. Bäz, K. Hecher, B.-J. Hackelöer (1999) Die klinische Bedeutung der fetalen Nackentransparenz Der Gynäkologe 32, 200-212 |
|
|
|
| Schwerpunktthema Screeningstudien |
|
| Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH (1998) UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 352, 343-6 |
|
|
|
| Schwerpunktthema Konsensus |
|
| Pauer, H.-U. und Rauskolb, R. (1999) Blutuntersuchung bei Schwangeren zur pränatalen Risikopräzisierung für Chromosomenanomalien und Neuralrohrdefekte (Triple-Test). Der Frauenarzt 40, 518-522 |
|
| Braulke, I. and Rauskolb, R. (1996) Blutuntersuchung bei Schwangeren zur pränatalen Risikopräzisierung für Chromosomenanomalien und Neuralrohrdefekte (Triple-Test). Med. Genetik 4, 348-352 |
|
| Braulke, I. and Rauskolb, R. (1995) Blutuntersuchung bei Schwangeren zur pränatalen Risikopräzisierung für Chromosomenanomalien und Neuralrohrdefekte (sog. Triple-Test). Bericht über die 2. Konsenstagung. Der Frauenarzt 36, 98-99 |
|
| Rauskolb, R. (1993) Blutuntersuchungen bei Schwangeren zur pränatalen Erkennung von Chromosomenanomalien und Neuralrohrdefekten (sog. Triple-Test). Der Frauenarzt 34, 254-258 |
|
| Andere Themen |
|
Wald NJ, Kennard A, Hackshaw A, McGuire A (1997) Antenatal screening for Down's syndrome.J Med Screen 4, 181-246 Kommentar: Review-Artikel
Published erratum appears in J Med Screen 1998;5(2):110 and 1998;5(3):166 |
|
|
|
|
|
|
|
